Loading...
•
Dec 31, 2019
Glaukos Q4 2019 Earnings Report
Glaukos reported strong Q4 2019 results with a 22% increase in net sales, driven by Glaucoma unit volume increases and the Avedro acquisition.
Key Takeaways
Glaukos Corporation announced its Q4 and full year 2019 financial results, highlighted by a 22% increase in net sales for the quarter, reaching $65.8 million. The growth was fueled by increased Glaucoma unit volume and the contribution from the Avedro acquisition. The company introduced 2020 net sales guidance of $290 million to $300 million.
Net sales increased by 22% to $65.8 million compared to Q4 2018.
Glaucoma net sales grew by 11% to $59.8 million compared to Q4 2018.
Corneal Health net sales reached $6.0 million from November 21, 2019, through December 31, 2019, following the Avedro acquisition.
The company provided 2020 net sales guidance of $290 million to $300 million.
Revenue by Segment
Forward Guidance
The company expects 2020 net sales to be in the range of $290 to $300 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...